Medtronic Inc. has agreed to pay $268 million to settle thousands of lawsuits that patients filed after a 2007 recall of a faulty heart defibrillator wire that caused at least 13 deaths.
The settlement announced Thursday covers some 8,100 personal injury lawsuits in both federal and state courts over Medtronic's popular Sprint Fidelis lead, which was implanted in some 235,000 people when the company recalled the device after a small number fractured. The malfunction could cause the defibrillator to stop working or to inappropriately shock patients -- a frightening and uncomfortable experience, but usually not life-threatening.
The cases had been lingering in a kind of legal limbo that began with a 2008 U.S. Supreme Court decision involving another Medtronic case that prevented many patients with faulty medical devices from filing suit against the makers of those products.
Rather than wait for a definitive resolution to various legal appeals, the Fridley-based medical technology giant agreed to end the three-year legal battle with a settlement. Spokesman Christopher Garland said, "Medtronic is pleased it was able to negotiate terms that were mutually agreeable to the parties."
Charles Zimmerman, a Minneapolis attorney who chaired the Plaintiffs' Steering Committee, called the settlement "an excellent example of what people can do when they act together to do the right thing for the public and for public health."
Part of a $5.8 billion global market that is firmly entrenched in Minnesota, implantable cardioverter defibrillators (ICDs) are stopwatch-sized devices that shock an errantly beating heart back into rhythm. Defibrillators have been a major segment for Medtronic, which brought in $15.8 billion in revenue in its last fiscal year. But sales of the devices have slowed in recent years due in part to industry-wide product recalls, as well as overall economic woes that have dampened demand.
The device is implanted in the chest and connected to the heart with one or a series of wires called leads. Since the recall, Medtronic has maintained that the best course of action for most patients with the potentially faulty lead is to leave it in the body -- and the company estimates that 170,000 leads are still implanted.
Because scar tissue can form around the leads, it is often difficult and somewhat risky to surgically remove them. Four of the 13 known deaths linked to the Sprint Fidelis lead can be attributed to the extraction surgery, the company said.